Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AMED CoROCO:7575 -0.48%55 EPS without NRI is NT$1.22 as of Dec. 2025. GuruFocus rates ROCO:7575 with a GF Score™ of 55/100 and a GF Value™ of NT$62.86 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 660 Medical Devices & Instruments companies, AMED Co ranks worse than 84.7% on this metric.
AMED Co's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was NT$0.70.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.22.
During the past 12 months, AMED Co's average earnings per share (NRI) Growth Rate was -34.70% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -23.30% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 1.10% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for AMED Co's EPS without NRI or its related term are showing as below:
ROCO:7575'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -23.3 Med: 19.9 Max: 44.9
Current: -23.3
During the past 7 years, AMED Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 44.90% per year. The lowest was -23.30% per year. And the median was 19.90% per year.
ROCO:7575's 3-Year EPS without NRI Growth Rate is ranked worse than 84.7% of 660
companies
in the Medical Devices & Instruments industry
Industry Median: 8.25
vs ROCO:7575: -23.30
AMED Co's EPS (Diluted) for the
six
months ended in Dec. 2025 was NT$0.96.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.19.
AMED Co's EPS (Basic) for the
six
months ended in Dec. 2025 was NT$0.96.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.19.
AMED Co (ROCO:7575) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
AMED Co EPS without NRI Related Terms
AMED Co EPS without NRI Historical Data
* Premium members only.
The historical data trend for AMED Co's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7575 vs ISRG, BDX, MDLN: EPS without NRI Comparison
For the Medical Instruments & Supplies subindustry, AMED Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AMED Co PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AMED Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where AMED Co's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$1.22
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMED Co (ROCO:7575) has a EPS without NRI of NT$1.22 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on AMED Co and its competitors. According to the industry distribution chart, AMED Co ranks #559 out of 660 companies in the Medical Devices & Instruments industry, placing it in the top 84.7%.
Is AMED Co's EPS without NRI too high?
AMED Co's current EPS without NRI is NT$1.22. Based on the distribution chart, AMED Co ranks #559 out of 660 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AMED Co has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AMED Co's EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AMED Co ranks #559 out of 660 companies for EPS without NRI. This places AMED Co in the lower half of its industry. The industry median EPS without NRI is 8.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.25, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on AMED Co and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AMED Co's current EPS without NRI is NT$1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AMED Co stock overvalued right now?
Based on GuruFocus' analysis, AMED Co (ROCO:7575) is currently considered Possible Value Trap. The stock's GF Value™ is NT$62.86, compared to a current price of NT$10.45 — trading 83.4% below its estimated fair value. The current EPS without NRI is NT$1.22. AMED Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For AMED Co (ROCO:7575), the current EPS without NRI is NT$1.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AMED Co (ROCO:7575) Overvalued in 2026?
Based on GuruFocus' analysis, AMED Co stock appears to be undervalued.
The current stock price of NT$10.45 is trading 83.4% below its estimated GF Value™ of NT$62.86.
GuruFocus considers AMED Co to be Possible Value Trap.
Key valuation signals for ROCO:7575:
EPS without NRI: NT$1.22
GF Value™: NT$62.86 vs. price of NT$10.45 (83.4% below fair value)
No single metric tells the full story. See the ROCO:7575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AMED Co Ltd is fully committed to the research and development of UV photopolymerized hydrogels. It is a professional research and development and manufacturing company of wound dressing materials, providing proper wound care solutions, and marketing the product under the brand of Heli Dressing.
55GF Score
Get the complete analysis for ROCO:7575
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7575 has been successfully added to your 
